Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: intramuscularly (IM injection) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

NCT02139657
View directory record Official record
Conditions
Rabies
Interventions
RIG-C
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 14, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influenza Vaccine in Pregnant Women

NCT00905125
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, Fluarix®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00427349
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
Interventions
AMG 706, octreotide
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
112
States / cities
Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT03778931
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Standard of Care
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
104
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Fullerton, California + 84 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

NCT03695237
View directory record Official record
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 14, 2026, 5:48 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07047716
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis
Interventions
Lenacapavir Injection, Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 14, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

NCT06620003
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
cAd3-Marburg Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

NCT07757802
View directory record Official record
Conditions
HIV
Interventions
DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT05743595
View directory record Official record
Conditions
Unmethylated Glioblastoma
Interventions
Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation device
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

NCT01438606
View directory record Official record
Conditions
HIV Infections
Interventions
VSV-Indiana HIV gag vaccine, Placebo injection (normal saline)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133
View directory record Official record
Conditions
Healthy
Interventions
Entolimod, Placebo, Influenza vaccine
Drug
Lead sponsor
Robert J. Pignolo
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 14, 2026, 5:48 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

NCT03382977
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
VBI-1901, Carmustine, Lomustine
Biological · Drug
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

NCT00799825
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
39
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Pneumococcal Vaccines in Patients With Asthma

NCT03260790
View directory record Official record
Conditions
Asthma
Interventions
PCV13, PPSV23
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00979602
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

NCT03499795
View directory record Official record
Conditions
Anal Neoplasm
Interventions
VGX-3100, CELLECTRA™ 5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 14, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT02518750
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Interventions
Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

NCT00955006
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 14, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616
View directory record Official record
Conditions
Alzheimer Disease
Interventions
JNJ-64042056, Placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
55 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 5:48 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

NCT03814590
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted medium dose, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted high dose, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, Placebo (Saline solution)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
18
States / cities
Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 14, 2026, 5:48 AM EDT